Vanguard Group Inc. Sells 253,037 Shares of Lantheus Holdings, Inc. $LNTH

Vanguard Group Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,699,381 shares of the medical equipment provider’s stock after selling 253,037 shares during the quarter. Vanguard Group Inc. owned 10.10% of Lantheus worth $445,844,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of LNTH. Hantz Financial Services Inc. raised its position in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the last quarter. First Horizon Corp purchased a new position in Lantheus during the 3rd quarter worth $26,000. Osterweis Capital Management Inc. purchased a new position in Lantheus during the 2nd quarter worth $36,000. Farther Finance Advisors LLC grew its stake in shares of Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lantheus in the 3rd quarter worth $55,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $85.82 on Wednesday. The firm has a market cap of $5.59 billion, a P/E ratio of 25.47 and a beta of -0.08. The firm has a 50-day moving average of $79.09 and a 200 day moving average of $68.41. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $108.90.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same quarter in the previous year, the firm posted $1.59 earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 4.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on LNTH shares. Mizuho raised their price target on shares of Lantheus from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Jefferies Financial Group restated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a report on Friday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.